Results 1 to 10 of about 19,342 (211)

The Discovery of α-Adrenoceptor Antagonists as a Potential New Treatment Option for Uveal Melanoma [PDF]

Biomolecules
Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Because of its high potential for spreading and its limited response to treatment, UM remains a clinical challenge. Previous studies suggest that clinical adrenergic receptor (AR)
Yilan He, Hongtao Liu, Ulrike Hendgen-Cotta, Tienush Rassaf, Nikolaos E. Bechrakis, Utta Berchner-Pfannschmidt   +5 more
doaj   +2 more sources

A sex-sensitive LC-MS/MS method with isotopic internal standard for prazosin bioequivalence: bridging precision medicine and generic drug policy in China [PDF]

Frontiers in Pharmacology
ObjectiveTo develop a rapid, sensitive, and high-throughput liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for prazosin quantification in human plasma, validate its application in bioequivalence studies, and investigate sex-specific ...
Hui Chen, Hui Chen, Junping Guo, Zhenyu Zhu, Xiaomei Huang, Jincai Guo, Jincai Guo   +6 more
doaj   +2 more sources

Prazosin dosed 3 times a day to treat flashbacks related to PTSD: A case report [PDF]

Mental Health Clinician, 2023
Prazosin is an alpha-1 adrenergic receptor antagonist widely known by mental health providers for its off-label use for nightmares in patients with PTSD.
Christie Richardson, DO, MS, Alexander Swartz, BA, Martin Forsberg, MD   +2 more
doaj   +1 more source

Evaluation of low dose prazosin for PTSD-associated nightmares in children and adolescents [PDF]

Mental Health Clinician, 2023
Introduction: Knowledge about fundamental sleep disorders and dysregulation that occurs in children with PTSD is limited. Prazosin is an alpha-1 receptor antagonist often used off label for the treatment of PTSD-associated nightmares in adults; however ...
Nancy Hudson, PharmD, Steven Burghart, DPh, RPh, MBA, BCPP, Jill Reynoldson, PharmD, BCPP, DPLA, Dennis Grauer, MS, PhD   +3 more
doaj   +1 more source

Prazosin for the management of behavioural and psychological symptoms of dementia

Drugs in Context, 2022
Prazosin, a centrally acting α1 adrenoceptor antagonist, has been included in two published algorithms amongst the list of medications that may be used in the management of behavioural and psychological symptoms of dementia (BPSD).
Rajesh R Tampi, Deena J Tampi, Syeda Arshiya Farheen, Mahwish Adnan, Dhweeja Dasarathy   +4 more
doaj   +1 more source

Case report: Prazosin augmentation for treating comorbid treatment-resistant depression and chronic post-traumatic stress disorder

Frontiers in Psychiatry, 2022
Psychological trauma in childhood can lead to post-traumatic disorder (PTSD) with protracted comorbid depression, which responds poorly to conventional antidepressants.
Ping Guo, Yu Fang, Ming Feng, Xudong Zhao, Shikai Wang, Mincai Qian, Juanjuan Huang, Huanxin Chen   +7 more
doaj   +1 more source

The Relative Effects of Prazosin on Individual PTSD Symptoms: Evidence for Pathophysiologically-Related Clustering

Chronic Stress, 2021
Background The α 1 -adrenoreceptor antagonist prazosin has in many but not all studies been found to be effective for PTSD associated nightmares, hyperarousal symptoms, and total symptom severity.
Rebecca C. Hendrickson, Steven P. Millard, Kathleen F. Pagulayan, Elaine R. Peskind, Murray A. Raskind   +4 more
doaj   +1 more source

Muting Bacterial Communication: Evaluation of Prazosin Anti-Quorum Sensing Activities against Gram-Negative Bacteria Pseudomonas aeruginosa, Proteus mirabilis, and Serratia marcescens

Biology, 2022
Quorum sensing (QS) controls the production of several bacterial virulence factors. There is accumulative evidence to support that targeting QS can ensure a significant diminishing of bacterial virulence.
Abrar K. Thabit, Khalid Eljaaly, Ayat Zawawi, Tarek S. Ibrahim, Ahmed G. Eissa, Samar S. Elbaramawi, Wael A. H. Hegazy, Mahmoud A. Elfaky   +7 more
doaj   +1 more source

Differences in the signaling pathways of α1A- and α1B-adrenoceptors are related to different endosomal targeting [PDF]

, 2013
Aims: To compare the constitutive and agonist-dependent endosomal trafficking of α1A- and α1B-adrenoceptors (ARs) and to establish if the internalization pattern determines the signaling pathways of each subtype.
A Hirasawa, AC Hanyaloglu, AL Lattion, B Lei, BL Wolfe, C Moyano, C Stenbergen, CD Wright, D Calebiro, D Chalothorn, D Diviani, D Gesty-Palmer, D Wu, DM Perez, DP Morris, DP Morris, E Oliver, EJ Adie, EJ Adie, Elena Carceller, F Liu, Fermí Montó, Graeme Milligan, Ian Christie McGrath, James Porter, JB Morris, JD Pediani, JD Pediani, JL Benovic, John Pediani, KA DeFea, L Stanasila, LM Luttrell, M von Zastrow, María Antonia Noguera, MC Lyssand JS De Fino, Miguel Pérez-Aso, MW Lee, MY Tsang, P Lajoie, PA Patel, Pilar D’Ocon, RH Oakley, RR Price, S Ahn, S Alexander, S Keffel, S Mhaouty-Kodja, S Terrillon, SK Shenoy, SM DeWire, SS Ferguson, TL Theroux, Vanessa Segura, Y Huang   +54 more
core   +9 more sources

Influence of prazosin on systemic iron levels and the associated iron metabolic alterations in spontaneously hypertensive rats

Pharmacology Research & Perspectives, 2022
The relationship between cardiovascular diseases and iron disorders has gained increasing attention; however, the effects of hypotensive drugs on iron metabolic alterations in hypertension are not well understood.
Hengrui Chang, Dong Zhang, Zhen Xin, Pengfei Zhang, Wenyuan Ding, Yan‐Zhong Chang   +5 more
doaj   +1 more source